RESEARCH, PUBLISHED ACADEMIC ARTICLES & PEER REVIEWS

THE THEORY BEHIND THE PRODUCTS

WE TRY & REPUBLISH THE MOST READABLE OF THE ACADEMIC WORKS FROM THE SCIENTISTS BEHIND FEATURED PRODUCTS PLUS THOSE WHO REVIEW THEM, HOWEVER BIASED THEIR VIEWS ARE FOR OR AGAINST

#CHITOMUR

#BLADDER

#URINARY INCONTINENCE #PROSTATE

[Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia]

V G Gomberg, V G Ryzhak, R V Liutov

PMID: 24640697

The blind randomized placebo-controlled study of the efficacy of bladder peptide bioregulator Chitomur for the treatment of older age groups of men with benign prostatic hyperplasia was conducted. The effect of the drug on the main urodynamic parameters, symptoms dynamic of the lower urinary tract function disturbances, prostate volume and the quality of life of men with benign prostatic hyperplasia in age from 62 to 83 years was evaluated. It was found that the course application of peptide bioregulator Chitomur in elderly and senile patients with benign prostatic hyperplasia significantly improves the basic parameters of urination. That was accompanied by improved quality of life of the patients. The achieved improvement of urodynamic parameters and quality of life does not reduce during the month following the end of treatment. No adverse effects of the drug were found during the study, which is important for elderly patients and distinguishes it from the conventional drugs used for the treatment of patients with benign prostatic hyperplasia.

PubMed Disclaimer

https://pubmed.ncbi.nlm.nih.gov/24640697/